209 related articles for article (PubMed ID: 35710646)
1. Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan.
Igarashi A; Maruyama-Sakurai K; Kubota A; Akiyama H; Yajima T; Kohsaka S; Miyata H
Diabetes Ther; 2022 Jul; 13(7):1367-1381. PubMed ID: 35710646
[TBL] [Abstract][Full Text] [Related]
2. Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence.
McEwan P; Bennett H; Khunti K; Wilding J; Edmonds C; Thuresson M; Wittbrodt E; Fenici P; Kosiborod M
Diabetes Obes Metab; 2020 Dec; 22(12):2364-2374. PubMed ID: 32744392
[TBL] [Abstract][Full Text] [Related]
3. SGLT2i as fourth-line therapy and risk of mortality, end-stage renal diseases and cardiovascular diseases in patients with type 2 diabetes mellitus.
Wong CKH; Tang EHM; Man KKC; Chan EWY; Wong ICK; Lam CLK
Diabetes Metab; 2021 Jul; 47(4):101196. PubMed ID: 33039672
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.
Varshney N; Billups SJ; Saseen JJ; Fixen CW
Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
[TBL] [Abstract][Full Text] [Related]
6. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Classes of Glucose-Lowering Medications on Renal Outcome in Type 2 Diabetes.
Takeuchi M; Ogura M; Minoura T; Inagaki N; Kawakami K
Mayo Clin Proc; 2020 Feb; 95(2):265-273. PubMed ID: 32029085
[TBL] [Abstract][Full Text] [Related]
8. Sex-Related Disparities in Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes and Heart Failure.
Hammer A; Hofer F; Kazem N; Koller L; Steinacher E; Baumer U; Wollmann F; Kautzky-Willer A; Beitl K; Remer F; Hengstenberg C; Niessner A; Sulzgruber P
J Womens Health (Larchmt); 2023 Nov; 32(11):1219-1228. PubMed ID: 37638826
[No Abstract] [Full Text] [Related]
9. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
[No Abstract] [Full Text] [Related]
10. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
11. Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
Guja C; Giorgino F; Blonde L; Ali A; Prázný M; Meier JJ; Souhami E; Lubwama R; Ji C; Rosenstock J
Diabetes Ther; 2022 Jan; 13(1):205-215. PubMed ID: 34894329
[TBL] [Abstract][Full Text] [Related]
12. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
[TBL] [Abstract][Full Text] [Related]
13. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry.
Li X; Hoogenveen R; El Alili M; Knies S; Wang J; Beulens JWJ; Elders PJM; Nijpels G; van Giessen A; Feenstra TL
Pharmacoeconomics; 2023 Oct; 41(10):1249-1262. PubMed ID: 37300652
[TBL] [Abstract][Full Text] [Related]
15. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Glucose-Lowering Therapies as Add-on to Standard Care for People With Type 2 Diabetes in Malaysia.
Sim R; Chong CW; Loganadan NK; Saidoung P; Adam NL; Hussein Z; Chaiyakunapruk N; Lee SWH
Value Health Reg Issues; 2023 Nov; 38():9-17. PubMed ID: 37419012
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of patients with diabetes and a history of myocardial infarction initiating PCSK9 and SGLT2 inhibitors.
Hubbard D; McKinley EC; Colantonio LD; Poudel B; Rosenson RS; Brown TM; Jackson EA; Huang L; Orroth KK; Mues KE; Dluzniewski PJ; Bittner V; Muntner P
Am Heart J Plus; 2022 Jan; 13():100121. PubMed ID: 38560067
[TBL] [Abstract][Full Text] [Related]
19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
20. Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study.
Tang EHM; Wong CKH; Lau KTK; Fei Y; Cheung BMY
Diabetes Res Clin Pract; 2021 Oct; 180():109071. PubMed ID: 34592391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
